INTRODUCTION

Epigallocatechin gallate (EGCG) is a major active compound in green tea and reportedly inhibits dietary glucose absorption into the blood by inhibiting small intestinal α-glucosidase but is unstable in gastric fluid. Hence, we formulated EGCG into enteric preparations that prevent release in gastric fluid.

METHODS

Granules were prepared using a wet granulation method and were formulated into polyvinylpyrrolidone (PVP)-Eudragit L100-55 (5:1; F1), PVP-Eudragit L100-55 (1:1; F2), and Eudragit L100-55 (F3) preparations using 30% w/w Eudragit L100-55 as a matrix. EGCG contents of granules were evaluated and dissolution tests were performed at pH 1.2 and 6.8.

RESULTS

F1–3 formulas had good flow properties and contained EGCG at 24.05%±0.15%–24.96%±0.28%. Dissolution tests showed that F1 and F2 formulas released EGCG at 50.53%±0.04% and 17.80%±0.55%, respectively, after 2 h in HCl medium at pH 1.2. Cumulative drug release from F1 and F2 formulations after 2 h under these conditions (pH 1.2) and 1 h in phosphate buffer (pH 6.8) was 94.40%±1.58% and 93.70%±1.08%, respectively.

CONCLUSION

As the optimal formula, F3 granules limited drug release to 7.03%±0.22% in HCl at pH 1.2 over 2 h and cumulative drug release in HCl medium (pH 1.2) followed by phosphate buffer (pH 6.8) of 86.13%±0.20%.

KEYWORDS: Delayed release, Enteric, Epigallocatechin gallate, Eudragit L100-55, Granules, Green tea (Camellia sinensis) extract.
Dissolution tests
Dissolution tests were performed as described previously [11,12] with various modifications. Representative gastric and duodenal fluids were produced in 100-mL aliquots using HCl (pH 1.2) and phosphate buffer (pH 6.8), respectively. After preparation in 150-mL glass beakers, HQ media at pH 1.2 were added to 1000-mL glass beakers containing 200 mL of water and were then heated on a hot plate to 37±0.5°C. Granule samples of 260 mg containing 65 mg of EGCG were placed in 2 cm×2-cm bags made of filter paper sewn with mattress thread. Bags were then placed an acid medium at 37±0.5°C and were stirred at 100 rpm using a magnetic stirrer. After 2 h, 2-mL aliquots were transferred to 100 mL of phosphate buffer (pH 6.8) at 37±0.5°C and were stirred at 100 rpm. After 15, 30, 45, and 60 min, 2-mL aliquots of buffer media were taken and replaced with phosphate buffer pH 6.8. Dissolved EGCG contents of phosphate buffer samples were then determined using high-performance liquid chromatography (HPLC).

Formulation of granules
Enteric granule formulae of green tea leaf extracts are listed in Table 2. Granules containing green tea leaf extract, Avicel pH 101 (as a filler), Eudragit L100-55, and PVP in the relative quantities listed in Table 2 were synthesized using the wet granulation method as described above.

Evaluation of enteric granules of green tea leaf extract
Organoleptic tests
Organoleptic tests included observations of shape, color, odor, and taste of the produced granules [13].

Granule size distribution tests
Size distributions of the granules were evaluated using sieve shakers. Briefly, series of five sieves with numbers 16, 25, 35, 45, and 60 were arranged in descending order from the largest sieve hole. Subsequently, 25-g granule samples were placed in the top sieve and the sieving machine was run for 10 min. Weights of fractions remaining in the sieves were recorded as described previously [14].

Flow properties
Angle of repose
Test samples of 100 mL were introduced into dry funnels with nozzles of 10 mm in diameter. The angle of repose was determined according to the United States Pharmacopeia 35. Specifically, an integrated driven laser of the Flow Tester was directed to the sidewall of the built-up cone of 10 mm in diameter. The angle of repose was determined according to the results of these preliminary tests, the optimal polymer concentration for resisting the release of active substance. Based on the results of these preliminary tests, the optimal polymer concentration for resisting the release of active substance into acid medium was 30%.

Calculation of compressibility indexes and Hausner ratios
Compressibility index values and Hausner ratios were calculated according to the United States Pharmacopeia 35 equations using apparent density data and tapped density tests. The results are shown in Table 3.

Determination of EGCG levels in granules
Instrumentation and operation conditions for HPLC
EGCG concentrations were determined using a Shimadzu HPLC column model LC6A with a SPD-6AV UV-Visible detector and a Kromasil column 100–5 C18 of 250 mm×4.6 mm. Samples of 20 µL were injected and eluted using a mobile phase comprising 0.05% acetic acid-acetonitrile (87:13 v/v) with a final pH of 3.5–4 and with a column temperature of 20±3°C and a flow velocity of 1 mL/min. Elutes were detected at a wavelength of 280 nm [15].

Determination of EGCG levels in granules
Granule samples of 1 g were grinded to obtain powder, of which 50-mg aliquots were diluted to 25 mL in volumetric flasks. Solutions were sonicated for 5 min, were filtered through Millipore filters to remove particles, and were then injected into the HPLC instrument. Tests were performed in triplicate and EGCG concentrations were calculated by entering measured areas under the curve into linear regression equations.

Dissolution tests
Dissolution tests were performed as described for optimization of total polymer concentrations in granule formulations.

RESULTS AND DISCUSSION
Optimization of total polymer concentrations in formulas
After treating granules in acid medium for 2 h, visual observation showed that enteric granule matrices containing polymer at 5% formed unfavorable soft masses at the bottoms of the containers (Fig. 1). Yet at polymer concentrations of 15% and 30%, granule shapes remained and did not become soft.

Formulas B (Eudragit L100-55 15%) and C (Eudragit L100-5 30%) were then tested for dissolution in HCl at pH 1.2 over 2 h. Formula B released 24.03±2.28% of the active substance into acid medium under these conditions, whereas formula C (30% Eudragit L100-55) released only 7.03±0.22% of the active substance in these conditions. Based on the results of these preliminary tests, the optimal polymer concentration for resisting the release of active substance into acid medium was 30%.

To improve on 30% Eudragit L100-55 matrices, we produced F1–3 formulas with PVP–Eudragit L100-55 ratios of 5:1, 1:1, and 0:1, respectively. The best of these formulas was used as the enteric preparation in dissolution tests.

| Material | Formula | Flowability (g/s) | Angle of repose (°) | Compressibility index (%) | Hausner ratio |
|----------|---------|------------------|--------------------|--------------------------|---------------|
|          |         |                  |                    |                          |               |
| 1        | 4.37±0.07 | 32.5±0.41        | 12.25±0.07         | 1.14±0.00                |               |
| 2        | 4.12±0.03 | 33.0±0.37        | 12.70±1.37         | 1.14±0.01                |               |
| 3        | 4.20±0.02 | 32.43±0.16       | 12.09±0.05         | 1.13±0.00                |               |

Table 4: Cumulative epigallocatechin gallate release

| Formula | Cumulative drug release in HCl medium at pH 1.2; mean±SD (%) | Cumulative drug release in HCl medium at pH 6.8; mean±SD (%) |
|---------|---------------------------------------------------------------|-------------------------------------------------------------|
| 1       | 50.53±0.04                                                   | 94.40±1.58                                                 |
| 2       | 17.80±0.55                                                   | 93.70±1.08                                                 |
| 3       | 7.0±0.22                                                     | 86.13±0.20                                                 |
The 4th International Conference on Global Health 2019

Anwar and Sherman

The 4th International Conference on Global Health 2019

Anwar and Sherman

Formulation of granules
Following manufacture with 100-g mixtures, F1–3 granules were yielded at 92.82, 91.52, and 90.45 g, respectively. The 8%-10% losses in mass reflect residues left in containers and sieves during manufacture.

Evaluation of granule masses

Organoleptic tests
The three granule formulas described herein had single large granular solid forms, were brownish-orange in color and had a green tea flavor with a slightly bitter taste.

Particle size distribution tests
Particle size distributions of F1–F3 granules were measured using multilevel sieves covering the range 0–1180 μm. The results of tests with 710–1180-μm sieves are shown in Fig. 2.

Particle size distribution tests ensure uniformity of contact surface areas with dissolution medium during dissolution testing, thus facilitating comparisons of granules.

Tests of flow properties
As shown in Table 3, flowabilities of granules were tested using various methods and properties of the formulations were characterized as precisely as possible. To identify differences in flow characteristics of the granules, we measured of angles of repose, performed flowability tests, and determined compressibility indexes and Hausner ratios.

The values for angles of repose, compressibility index, and Hausner ratios were similar for all granules (Table 3). Moreover, all prepared formulations had good flow properties, with angles of repose within 31°–35°, compressibility indexes of 11%–15%, and Hausner ratios of 1.12–1.18.

Determination of EGCG levels in granules
EGCG levels were determined by grinding 1 g of granules and then diluting 50-mg samples (equivalent to 12.5 mg EGCG) in 25 mL of mobile phase. EGCG contents of F1–3 preparations were 24.05%±0.15%, 24.78%±0.14%, and 24.96%±0.28%, respectively.

Dissolution test
To evaluate drug release profiles from granules, we set up calibration curves of EGCG standard solutions in acid (pH 1.2) and phosphate buffer (pH 6.8). These gave linear concentration curves following the equations $y=21626x+103950$ (r=0.9998) and $y=20691x–128135$ (r=0.9999), respectively.

Dissolution profiles of granules from F1–3 preparations in acid for 2 h followed by phosphate buffer for up to 60 min are shown in Fig. 3.

The dissolution profiles of EGCG in Fig. 3 show that F1 and F2 granules containing green tea leaf extracts failed to prevent release of the drug in acidic medium, releasing 50.53%±0.04% and 17.80%±0.55% of active compound, respectively. In contrast, the F3 formula comprising Eudragit L100-55 at 30% cumulatively released only 7.03%±0.22% of the active compound over 2 h in an acid medium.

Addition of PVP at 5 times, the concentration of Eudragit L100-55 (5:1) led to greater release of the drug in acid medium over 2 h. These observations can be explained by the predominance of PVP over Eudragit L100-55 as the matrix constituent polymer. Under these conditions, the matrix was eroded in acidic medium because PVP polymers are pH-sensitive, although PVP can act as a binder [9]. In F2 preparations, the percentage of drug release in acid media was smaller than from F1 preparations. Thus, additional Eudragit L100-55 concentrations in the matrix can reduce drug release in acid medium. F2 was better able to withstand drug release in acidic medium than F1, although it still released >10% of the active compound. These results show that 5:1 and 1:1 combinations of PVP and Eudragit L100-55 in granule matrices are not optimal for preventing drug release in acid medium over 2 h. The granules with a matrix consisting of 30% Eudragit L100-55 are at least released from the granules at pH 2.

Cumulative drug release from F1 and F2 preparations was higher than from F3, as shown in Table 4. Similarly, previous research [7,10] showed that higher Eudragit L100-55 concentrations in the formulation reduce dissolution rates. Accordingly, at low pH, Eudragit L100-55 does not dissolve and drug release is regulated by diffusion of the active substance from the matrix. At higher pH, drug release is affected...
by Eudragit L100-55 polymer solubilization and degradation of the matrix [10]. Therefore, higher Eudragit L100-55 concentrations in F3 likely require longer dissolution times to achieve the same cumulative release as from the Eudragit L100-55 formulas F1 and F2.

CONCLUSION

Enteric granules formulated with 30% w/w Eudragit L100-55 as a matrix polymer released only 7.03%±0.22% of their drug contents in acidic medium over 2 h but cumulatively released 86.13%±0.20% of drug contents after a further hour in phosphate buffer at pH 6.8.

CONFLICTS OF INTEREST

We declare that we have no conflicts of interest.

REFERENCES

1. Liu S, Yu Z, Zhu H, Zhang W, Chen Y. In vitro α-glucosidase inhibitory activity of isolated fractions from water extract of Qingzhuan dark tea. BMC Complement Altern Med 2016;16:378.
2. Forester SC, Gu Y, Lambert JD. Inhibition of starch digestion by the green tea polyphenol, (-)-epigallocatechin-3-gallate. Mol Nutr Food Res 2012;56:1647-54.
3. Onose S, Ochi M, Yamada S. Development of (-)-epigallocatechin-3-gallate (EGCG)-loaded enteric microparticles with intestinal mucoadhesive property. Int J Pharm 2011;410:111-3.
4. Zeng L, Ma M, Li C, Luo L. Stability of tea polyphenols solution with different pH at different temperatures. Int J Food Prop 2016;20:1-8.
5. Lieberman H, Lachman L, Schwartz J. Pharmaceutical Dosage Forms. New York: Marcel Dekker, Inc.; 1989.
6. Khutle NM, Pole S, Hasnak P, Rathod N, Bendale S. A Detail understanding of enterik coated granul: Manufacturing and evaluation. Eur J Pharm Med Res 2016;3:135-44.
7. Varshosaz J, Kennedy R, Gipps E. Use of enteric polymers for production of microspheres by extrusion-spheronization. Pharm Acta Helv 1997;72:145-52.
8. Rowe R. Handbook of Pharmaceutical Excipients. London, UK: Pharmaceutical Press; 2009.
9. Rojas J, Gonzalez C, Rico C, Saez O. Formulation of a modified release merformin. HCL matrix tablet: Influence of some hydrophilic polymers on release rate and in-vitro evaluation. Braz J Pharm Sci 2011;47:483-93.
10. Andrews G, Jones D, Diak O, McCoy C, Watts A, McGinity J. The manufacture and characterisation of hot-melt extruded enteric tablets. Braz J Pharm Sci 2008;69:264-73.
11. Cao Y, Teng J, Selbo J. Amorphous solid dispersion of epigallocatechin gallate for enhanced physical stability and controlled release. Pharmaceuticals (Basel) 2017;10:88.
12. Kotla NG, Singh S, Maddiboyina B, Sunnapu O, Webster TJ. A novel dissolution media for testing drug release from a nanostructured polysaccharide-based colon specific drug delivery system: An approach to alternative colon media. Int J Nanomed 2016;11:1089-95.
13. Rahmawati I, Pribadi P, Hidayat I. Formulasi dan evaluasi granul effervescent ekstrak daun binahong (Anredera cordifolia [Tenore] Steen.). Pharmaciana 2016;6:139-48.
14. Wu Y, Li X, Che T, Zhu Z, Kang J. The United States Pharmacopoeia 35; The National Formulary 30. Rockville, Md: United States Pharmacopeial Convention; 2012.
15. Fangueiro J, Parra A, Silva A, Egea M, Soutto E, Garcia M, et al. Validation of a High performance liquid chromatography method for the stabilization of epigallocatechin gallate. Int J Pharm 2014;475:181-90.